Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics by Kine Marita Knudsen Sand et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 26 January 2015
doi: 10.3389/fimmu.2014.00682
Unraveling the interaction between FcRn and albumin:
opportunities for design of albumin-based therapeutics
Kine Marita Knudsen Sand 1,2, Malin Bern1,2, Jeannette Nilsen2,3, HannaTheodora Noordzij 1,2,
Inger Sandlie1,2 and JanTerje Andersen2*
1 Department of Biosciences, Centre for Immune Regulation (CIR), University of Oslo, Oslo, Norway
2 Department of Immunology, Centre for Immune Regulation (CIR), Oslo University Hospital Rikshospitalet, Oslo, Norway
3 Institute of Clinical Medicine, University of Oslo, Oslo, Norway
Edited by:
Swapan K. Ghosh, Indiana State
University, USA
Reviewed by:
Peter Timmerman, Pepscan
Therapeutics B.V., Netherlands
So-Yon Lim, Harvard Medical School,
USA
Swapan K. Ghosh, Indiana State
University, USA
*Correspondence:
JanTerje Andersen, Oslo University
Hospital Rikshospitalet, Department
of Immunology, Sognsvannveien 20,
0027 Oslo, Norway
e-mail: j.t.andersen@medsin.uio.no
The neonatal Fc receptor (FcRn) was first found to be responsible for transporting antibod-
ies of the immunoglobulin G (IgG) class from the mother to the fetus or neonate as well as
for protecting IgG from intracellular catabolism. However, it has now become apparent that
the same receptor also binds albumin and plays a fundamental role in homeostatic regula-
tion of both IgG and albumin, as FcRn is expressed in many different cell types and organs
at diverse body sites. Thus, to gain a complete understanding of the biological function of
each ligand, and also their distribution in the body, an in-depth characterization of how FcRn
binds and regulates the transport of both ligands is necessary. Importantly, such knowledge
is also relevant when developing new drugs, as IgG and albumin are increasingly utilized
in therapy.This review discusses our current structural and biological understanding of the
relationship between FcRn and its ligands, with a particular focus on albumin and design
of albumin-based therapeutics.
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INTRODUCTION
Albumin and immunoglobulin G (IgG) are the two most abun-
dant circulating proteins in the bloodstream, and account for an
incredible 80–90% of the total protein pool. In addition, both
share an extraordinary long serum half-life, which in humans
amount to 19–21 days (1–3). While IgG is solely produced by
B and plasma cells in response to foreign substances, such as
pathogens, and is absolutely fundamental for protection against
infections, albumin is produced by hepatocytes of the liver and
acts as a multi-carrier of a plethora of insoluble and hydropho-
bic endogenous and exogenous ligands, such as ions, fatty acids,
amino acids, and waste products as well as a range of biomed-
ical drugs. In addition, albumin maintains the osmotic blood
pressure, is an important antioxidant, and possesses enzymatic
properties (4–6).
Despite their completely unrelated structures and biological
roles, IgG and albumin share two common and unique features;
extended serum half-life and an inverse relationship between
serum concentrations and half-life (1–3). These characteristics
were initially proposed to be caused by the presence of specific
saturable receptor-mediated mechanisms that would protect the
proteins from intracellular degradation (7, 8). And indeed, it
Abbreviations: β2m, β2-microglobulin; AP-2, adaptor protein 2; ABD, albumin-
binding domain; BBB, blood–brain-barrier; DCs, dendritic cells; DARPin, designed
ankyrin repeat protein; ER, endoplasmic reticulum; FcRn, neonatal Fc receptor;
GLP-1, glucagon-like peptide-1; gp, glycoprotein; HC, heavy chain; HER2, human
epidermal growth factor receptor 2; IgG, immunoglobulin G; Ii, invariant chain;
MHC, major histocompatibility complex; scFv, single-chain variable fragment; TGF,
transforming growth factor; TNF, tumor necrosis factor.
later became apparent that a broadly expressed cellular receptor,
then named the neonatal Fc receptor (FcRn), does exist and is
responsible for salvaging both IgG and albumin from cellular
catabolism via strictly pH-dependent recycling and transcytosis
pathways. Thus, FcRn plays a key role in homeostatic regulation of
these unrelated soluble proteins, securing a broad biodistribution
throughout the body of both molecules (9–13).
Due to its well-recognized serum stability and longevity, albu-
min has been utilized as a carrier for drugs for a long time, either
by direct genetic fusion or conjugation, or by non-covalent associ-
ation of the drug to albumin (14–16). However, during the devel-
opment of these strategies, the importance of the FcRn-dependent
mechanisms for drug pharmacokinetics and pharmacodynamics
was not really taken into account, as they were established before
the FcRn–albumin relationship was appreciated. Now, care must
be taken that the FcRn interaction is not disrupted when albumin-
based therapeutics are designed and evaluated. In addition, we
have shown that there are large differences in cross-species bind-
ing characteristics of human albumin to mouse and rat FcRn that
compromise preclinical in vivo evaluations in rodents (17, 18).
Thus, the pharmacokinetics and pharmacodynamics of a numer-
ous human albumin-based therapeutics may have to be reassessed,
and their FcRn binding ability and transport properties at differ-
ent body sites taken into account. Furthermore, unmasking the
molecular interaction of FcRn with albumin has given rise to new
classes of engineered albumin variants with altered FcRn binding
and transport capacities. Last, but not least, FcRn is well known
to mediate transport of IgG across cellular barriers such as polar-
ized epithelial cells covering mucosal surfaces and the placenta
(19–24), which have been successfully utilized as gateways for oral,
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nasal, pulmonary, and in utero delivery of IgG-based therapeutics
and vaccines (25–32). Whether albumin can be efficiently shuttled
by FcRn via these pathways has not yet been fully addressed and
needs to be explored, as such routes may be attractive for deliv-
ery of albumin-based therapeutics. In this review, we describe the
current molecular and cellular understanding of FcRn and its rela-
tionship with its ligands with a particular focus on albumin biology
and design of albumin-based therapeutics.
THE HISTORY OF FcRn
F.W. Rogers Brambell (1901–1970) was the first to postulate the
presence of a cellular receptor responsible for active prenatal trans-
port of IgG from the mother to the fetus across the yolk sac in
rabbits and across the intestine of neonatal rats (7, 33). This was
based on experiments done in his own laboratory as well as work
done by others, which showed that maternal IgG derived from
mother’s milk was absorbed from the gut lumen of neonatal rats
for up to 18–21 days post birth before the transport rapidly ceased
(34). Also, using in vitro intestinal cell assays, it was shown that
the transport was highly selective for the IgG isotype and solely
dependent on the constant Fc part (35). Based on these observa-
tions, Brambell proposed that a single cellular receptor was the
key player in mediating transcytosis of IgG over these cellular
barriers (7).
Furthermore, Fahey and Robinson demonstrated that IgG
was eliminated from the blood circulation in a concentration-
dependent manner, as injection of high doses of IgG in mice
greatly accelerated the clearance of endogenous IgG, while excess
amounts of IgA, IgM, or serum albumin did not (36). Again,
the process was fully dependent on Fc. Brambell recognized the
resemblance between this work and his own studies, and pro-
posed that a common receptor was responsible for transepithe-
lial and materno-fetal transport, as well as for serum half-life
regulation (7, 37).
During the 1970s, it was shown that transport of IgG across the
intestinal epithelium of the neonatal rat was strictly pH dependent,
as IgG uptake from the mother’s milk for delivery to the offspring
would only happen at acidic intestinal pH and not at physiolog-
ical pH (38). Almost 10 years later, the receptor in question was
identified in tissue from the neonatal rodent gut as a heterodimeric
protein consisting of 40–46 and 12 kDa subunits (39). This was fol-
lowed up by cloning of the corresponding genes, which revealed
that the 12 kDa subunit was β2-microglobulin (β2m) while the
larger subunit was a heavy chain (HC) related to the major histo-
compatibility complex (MHC) class I (40). The discovery inspired
its name FcRn.
As a parallel to postnatal transport across the neonatal intestine
and the prenatal transport of IgG across the yolk sac of rabbits,
a human ortholog of FcRn was cloned from syncytiotrophoblasts
of the human placenta by Story and colleagues (41), and shown
to direct transcytosis of mothers IgG to the fetus during the third
trimester of pregnancy (24). In all cases, FcRn-mediated transcy-
tosis ensures transfer of passive immunity to the fetus and the
newborn. However, FcRn function is not restricted to neonatal
life, as a large body of evidence has shown that it is expressed in
a range of cell types in all species studied throughout life (20, 21,
23, 30, 42–53).
In contrast to the well characterized FcRn–IgG relationship,
an explanation for the long half-life of albumin was missing
for decades. Brambell did only briefly touch upon albumin, but
did not discuss its catabolic rate (54). Instead, during the 1960s,
Schultze and Heremans postulated that the proposed mechanism
for IgG protection from degradation could also explain the correla-
tion between the half-life and concentration-dependent catabolic
rate of albumin (8). This was based on studies of the relative cata-
bolic rates of IgG and albumin in patients suffering from agamma-
globulinemia and analbuminemia. The work was largely ignored
until Anderson and co-workers reported that FcRn binds albumin
(11). The interaction was identified by chance when bovine albu-
min was co-eluted with recombinant soluble human FcRn from
an IgG affinity column (11, 55). Like the FcRn–IgG interaction,
the FcRn–albumin interaction is remarkably pH dependent (11,
56, 57). Whereas it was already known that mice, which do not
express a functional FcRn, catabolize IgG more rapidly than nor-
mal mice (9, 10, 58), the same rapid catabolic rate was now shown
also for albumin (11).
THE ARCHITECTURE OF FcRn
The neonatal Fc receptor is a transmembrane heterodimeric pro-
tein with a structure similar to that of classical and non-classical
MHC class I molecules (40). Specifically, it consists of a HC
with three extracellular domains (α1, α2, and α3), followed by
a transmembrane part and a cytoplasmic tail. The soluble sub-
unit β2m, which is common for almost all MHC class I molecules,
is non-covalently paired with the FcRn HC. An overview of the
crystal structures of truncated rat and human FcRn is shown in
Figures 1A–C.
Inspections of solved crystal structures of soluble truncated
recombinant forms of rat and human FcRn have revealed that the
extracellular part of the HC has a membrane proximal α3-domain,
followed by an amino-terminal α1–α2 platform that is made up
of eight antiparallel β-strands with two α-helices on top (59–65).
Further, β2m associates with the HC by making contacts with the
α3-domain, located below the α1–α2 platform. Proper folding of
the heterodimer in the endoplasmic reticulum (ER) is facilitated
by Erp57 and calnexin, and has been shown to be a prerequisite
for exit from the ER, and subsequent pH-dependent binding to
the ligands (66–68).
In contrast to classical MHC class I molecules that present pep-
tides bound in a groove located between the two α-helices on top
of the α1–α2 platform, the corresponding groove is occluded in
FcRn (60, 62). Instead, FcRn has evolved to bind IgG and albu-
min at separate binding sites on opposite sides of the α1 and α2
domains (57, 64, 69, 70) (Figure 1A). Furthermore, the human HC
contains only one putative N-glycosylation site (N102) compared
with four sites in the mouse and rat ectodomains (N87, N104,
N128, and N225) (40, 59) (Figures 1A,B), and the differential
glycosylation pattern of human and rat FcRn has been linked to
different sorting and distribution in polarized cells (71). The dif-
ferences in the glycosylation pattern results in molecular weights
of 51 and 45 kDa for the mouse and human HC, respectively.
Crystal structures of human FcRn have been solved at both
acidic and basic pH (59–61), as well as in complex with both lig-
ands (64, 69, 72), which show that there are few structural main
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FIGURE 1 | Crystallographic illustrations of rat and human FcRn. Crystal
structures of truncated (A) rat FcRn solved at pH 6.5, (B) human FcRn solved at
pH 8.2, and (C) pH 4.2. The FcRn HC is shown in green and the β2m subunit in
gray (A–C). The three domains of FcRn are denoted as α1, α2, and α3. The key
amino acid residues involved in binding to IgG are shown as blue spheres
(L112, E115, E116, W131, P132, and E133, human numbering), while the
residues central for albumin binding (W51, W53, W59, and W61) are shown as
red spheres. The loop containing the tryptophans is pH dependently regulated
by H166 (H168 in rat) within the α2-domain (yellow spheres, human
numbering). The close-ups show how H166 (H168 in rat) stabilizes the loop of
amino acid residues corresponding to residues 51–61 of the α1-domain by
forming charged interactions with E54 and Y60 at acidic pH. These interactions
are not seen in the crystal structure solved at basic pH, which results in an
unstructured loop (B). The four putative N-glycosylation sites of rat FcRn are
shown in orange spheres (N87, 104, 128, and 225), while only one
N-glycosylation site is found in human FcRn (N102). (D) An amino acid
sequence alignment of the cytoplasmic tail of FcRn from human, rat, and
mouse. The tryptophan and the di-leucine based sorting motifs that interact
with the adaptor protein 2 are highlighted in green. Amino acid residues
required for calmodulin binding are marked in red (human numbering). The
figures were made using PyMol, with the following PDB files; Rat FcRn pH 6.5:
3FRU (59), human FcRn pH 8.2 1EXU (60), human FcRn pH 4.2: 3MIB (61).
chain alterations in FcRn as a function of pH, except for a loop
within the α1-domain that is only solved at acidic pH (60, 61)
(Figures 1B,C). This loop has been shown to be important for
binding of albumin (discussed below). Binding of both ligands
is strictly pH dependent, with strong binding at acidic pH that
becomes progressively weaker near neutral pH, suggesting that
protonation of histidine residues, which is the only amino acid
that changes charge between pH 5.5 and 7.4, is responsible for
intra-molecular interactions or direct engagement with ligands.
The cytoplasmic tail of the HC contains conserved sorting
motifs that are important for trafficking of the receptor, including
di-leucine (L322/L323) and tryptophan (W311) motifs (73). An
overview of the stretch of amino acids corresponding to the cyto-
plasmic tails of mouse, rat, and human FcRn HCs is highlighted
in Figure 1D. The tryptophan motif has been demonstrated to
interact with the µ subunit of adaptor protein-2 (AP-2) while the
di-leucine motif interacts with the σ and γ subunits of AP-2 (74).
These motifs play a role in rapid endocytosis of the receptor from
the plasma membrane into endosomes, and basolateral targeting
in polarized rat cells. However, as there are cross-species differ-
ences in polarized expression of FcRn in human and rodent cell
lines (74–79), additional differences such as the variations in gly-
cosylation patterns may play a role in trafficking of the receptor.
Indeed, a study by Kuo and colleagues show that the difference in
polarized expression between rat and human FcRn may at least
partly be explained by the three additional N-glycosylation sites
found in rats (71).
Another motif in the cytoplasmic tail that is conserved among
species is a calmodulin binding sequence encompassing R300 and
R302 (Figure 1D). Targeting of the motif by mutagenesis resulted
in altered transport and decreased stability of the receptor (80). As
binding of calmodulin to FcRn is highly regulated by the flux of
calcium, it may be a way to modulate endosomal FcRn sorting. In
addition, as calmodulin will mask a putative amphipathic α-helix
in the cytoplasmic tail of FcRn, which for other proteins has been
shown to be inserted into the cell membrane and induce or sense
curvature, it may add another level of regulation of cellular sorting
of the receptor (80, 81).
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THE STRUCTURE OF ALBUMIN
Albumin is exclusively synthesized and secreted into the blood-
stream by liver hepatocytes to a concentration of 40 mg/ml in
both mouse and man (4). It is a highly soluble and stable protein
that is non-glycosylated and has a molecule weight of 66.5 kDa.
X-ray crystallographic structures of human albumin has revealed
that it is a heart-shaped molecule consisting of a single polypep-
tide of 585 amino acids with 17 pairs of disulfide bridges and 1
free cysteine (C34) (82–84). An illustration of the crystal struc-
ture of human albumin is shown in Figure 2. Albumin consists of
67% α-helices and no β-sheets, and folds into three homologous
domains named DI, DII, and DIII, where each is divided into A
and B subdomains (DIA, DIB, DIIA, DIIB, DIIIA, and DIIIB) (85).
The domains are connected via long flexible loops.
THE FcRn–ALBUMIN INTERACTION
When Chaudhury and colleagues co-eluted bovine albumin with
soluble human FcRn from a human IgG-coupled column (11), this
indicated that both ligands could bind the receptor simultaneously
FIGURE 2 |The crystal structure of human albumin. The illustration
shows the crystal structure of human albumin solved in the presence of
saturating amounts of palmitic acid. The α-helical structures of the three
domains (DI, DII, and DIII) are divided into subdomains (A and B) as
indicated. DI (pink) contains the fatty acid binding site 1, the free cysteine
(C34), and drug binding site 3. Fatty acid site 2 is located at the interface
between DI and DII. The metal binding site is located between subdomain
DIA and DIIA. DII (orange) contains the drug binding site 1 (Sudlow’s site 1)
as well as fatty acid sites 6 and 7. DIII (blue) contains fatty acid binding sites
3 and 4, the drug binding site 2 (Sudlow’s site 2) in DIIIA, and the fatty acid
biding site 5 in DIIIB. Examples of the binding sites for endogenous and
exogenous ligands for which crystal structures have been solved are listed
in green and red, respectively, as reviewed in Ref. (86). The figure was
designed using PyMol and the crystal structure data of human albumin
solved in the presence of palmitic acid with the PDB file 1E7H (87). CMPF,
carboxy-4-methyl-5-propyl-2-furanpropionic acid; NO, nitric oxide.
as a ternary complex. Subsequently, in vitro interaction analyses
demonstrated this indeed to be the case. Initial mapping of the
albumin binding site on human FcRn showed that a fully con-
served H166, within the α2-domain of the human FcRn HC, was
crucial for binding (56). An explanation for this finding was given
upon scrutiny of two crystal structures of human FcRn, one of
which was solved at pH 4.2, while the other was solved at pH 8.2
(60, 61). An overview of these two crystal structures are shown in
Figures 1B,C. A comparison of the two structures revealed that a
loop surrounding H166 within the α1-domain was only defined
in the structure solved at acidic pH (61), and not in the structure
solved at basic pH (60). This suggested that the configuration of
the loop is pH sensitive and stabilized at acidic pH when H166
is protonated and able to form hydrogen bonds with E54 and
Y60 (70) Figures 1A–C shows close-ups of the structural areas
surrounding H166 and the pH sensitive loop of human and rat
FcRn. The importance of these stabilizing interactions was con-
firmed by mutating E54 to a glutamine, which resulted in low
detectable binding of albumin (70). Furthermore, the loop con-
tains four conserved hydrophobic residues; W51, W53, W59, and
W61, which are partially or fully surface-exposed (Figures 1B,C).
Targeted mutagenesis of these tryptophan residues has demon-
strated their fundamental role in binding of albumin, as swapping
to alanine residues considerably reduced or abolished binding (72,
88). This means that the interaction is not only pH dependent but
also hydrophobic in nature. In line with this is a previous report
showing that the interaction has a large positive change in entropy,
indicative of a hydrophobic character (57). The findings strongly
support that H166 has a key regulatory role in stabilizing the loop
with the cluster of tryptophan residues that directly take part in
binding of albumin.
The principal binding site for FcRn on albumin was first shown
to be located within the C-terminal DIII, as removal of this domain
eliminated binding of albumin (70, 89). Then, targeting three
fully conserved histidine residues within DIII of human albumin
(H464, H510, and H535) by site-directed mutagenesis revealed
that all are crucial for binding (70). In addition, mutating a lysine
in position 500 (K500A), located within an extended loop that con-
nects the two subdomains of DIII, was shown to reduce binding
to FcRn by more than 30-fold (70). Furthermore, when recom-
binant variants of the three human albumin single domains were
tested for binding to FcRn, DIII was the only domain that showed
detectable binding, although with a more than 10-fold weaker
affinity than full-length albumin (70). Despite limited structural
knowledge, a docking model of the human FcRn–human albumin
complex was built, where in addition to DIII, two exposed loops
within the N-terminal DI were shown to be in proximity to the
receptor (70).
In agreement with these predictions, two recently published co-
crystal structures of human FcRn in complex with human albumin
confirmed the contributions from both DI and DIII,while DII does
not take direct part in the interaction (69, 72). One of the co-crystal
structures shows wild-type albumin, and the Fc part of IgG in com-
plex with FcRn (69), and an illustration of the ternary complex is
given in Figure 3. The other co-crystal shows an engineered human
albumin variant (HSA13) comprising four amino acid substitu-
tions (V418M, T420A, E505G, and V547A) (72). The latter was
Frontiers in Immunology | Immunotherapies and Vaccines January 2015 | Volume 5 | Article 682 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sand et al. The FcRn–albumin relationship
FIGURE 3 |The co-crystal structure of human FcRn bound to IgG–Fc
and albumin. The illustration shows the ternary complex of human FcRn
in complex with IgG Fc and wild-type human albumin. The three domains
of the FcRn HC (α1, α2, and α3) are shown in green and the β2m subunit
in gray. The IgG–Fc is shown in blue while the three domains of albumin
are shown in pink (DI), orange (DII), and light blue (DIII). H166 that
stabilizes the structure of the loop containing W51, W53, W59, and W61 is
shown in yellow. The FcRn residues W53 and W59 are shown as red
spheres. (A) FcRn–W59 makes contacts with a hydrophobic pocket in
DIIIA, which is composed of T467, T422, V426, L460, L463, and H464.
(B) FcRn–W53 makes hydrophobic stacking with three phenylalanines in
DIIIB (F507, F509, and F551). (C) A close-up of the structural areas of DI
with N111 and N109 of albumin DI interacting with the FcRn residues S58
and K63, respectively. (D) A close-up of the structural interface showing
the intramolecular hydrogen bond between albumin R81 and D89, and the
interaction between FcRn–T153 and R81. The figures were made using
PyMol and the crystal structure data of human FcRn in complex with
IgG–Fc and albumin (4N0U) (69).
selected by yeast display and has considerably improved affinity
for FcRn at both pH 6 and pH 7.4. The two co-crystal structures
show highly similar modes of binding, but with some differences
that are likely due to the introduced mutations in HSA13 DIII.
However, the hydrophobic cores of the interaction interfaces are
similar, and in both, the exposed FcRn–W53 and FcRn–W59 make
contact with hydrophobic pockets in DIIIB and DIIIA, respectively
(Figures 3A,B). More specifically, FcRn–W59 forms hydrophobic
interactions with T422, V426, L460, L463, and T467 in albumin
DIIIA (Figure 3A), while FcRn–W53 is inserted into a hydropho-
bic pocket between two α-helices in DIIIB, which comprises three
phenylalanine residues F507, F509, and F551 as well as T508
and T527 (69) (Figure 3B). The crucial residue K500 interacts
with E46 within the α1-domain of FcRn, as well as forming an
intra-molecular interaction with E531 of DIIIB (69). Further, the
interaction of FcRn–W53 with albumin requires a conformational
change in albumin that comprises residues 500–510, which are
part of a long loop that connects DIIIA and DIIIB. The two key
residues H510 and H535 are located within this loop, and take
part in the pH regulation of the FcRn–albumin interaction by sta-
bilizing the position of the loop at acidic pH, which subsequently
allows insertion of FcRn–W53 into DIIIB (69). In addition, H510
interacts with the fully conserved W176 and N173 in human FcRn
(69). The third histidine, H464, is part of a hydrophobic envi-
ronment that accommodates FcRn–W59 (69). Interestingly, the
binding site for fatty acids within DIII overlap with the interaction
sites for FcRn–W59 and FcRn–W53 (72) (discussed later).
Furthermore, both co-crystal structures show that two exposed
loops within DI of albumin are in contact with residues of the
α1–α2 helices of FcRn. In the wild-type complex, N109 and N111
form contacts with K63 and S58 of FcRn, respectively (Figure 3C).
Albumin D89 and R81 form an intramolecular hydrogen bond,
and R81 interacts with T153 of the receptor (Figure 3D). Notably,
N111 has different conformations in the two co-crystals and may
thus have alternative orientations. However, these studies did not
experimentally address the impact of DI (69, 72). Although the
docking model does not completely resemble the experimental
crystal structures, it has guided the mapping of structural areas on
both the receptor and albumin that are important for the inter-
action (70). Moreover, targeting of residues within the DI loops
by site-directed mutagenesis has confirmed that the loops indeed
contribute to FcRn binding (90).
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Interestingly, the crystal structures also suggest that albumin
may make contact with the β2m subunit, which involves long-
range interactions between β2m–R12 and E50 with the side chain
of albumin E505 and the backbone carbonyl of F502 (69). Again,
differences are seen between the complexes containing wild-type
albumin and HSA13. In one of the HSA13 complexes, K573, which
is located in the middle of the last α-helix of albumin, interacts
with β2m–E69 and S20 (72). Curiously, this interaction is not
found in the other complexes.
Further, Oganesyan and colleagues have reported a co-crystal
structure of human FcRn in complex with both wild-type albumin
and an Fc fragment derived from an engineered IgG variant with
improved binding to the receptor (69). As previous data have sug-
gested, the mode of albumin binding is not altered in the presence
of IgG (69).
THE LIGAND BINDING PROPERTIES OF ALBUMIN
The three domains of albumin contain binding pockets for a
plethora of small endogenous and exogenous substances (6, 86).
Thus, albumin acts as a molecule-taxi that transports essential
substances and waste products in the bloodstream to their target
sites. An illustration of a crystal structure of human albumin in
complex with fatty acids is shown in Figure 2. Although the three
domains are similar in structure, the interfaces are not, meaning
that the orientation of DII relative to DI is different from the
orientation of DIII relative to DII (84). In regard to binding of
fatty acids, it has been shown that there are seven binding sites
distributed asymmetrically throughout the tertiary structure of
albumin (84, 87, 91) (Figure 2). Furthermore, crystallographic
studies have shown that there are variations in the relative orien-
tation of the domains, which likely arises from inherent flexibility
of the loops and the domains. For instance, the structure of defat-
ted human albumin has been determined in three distinct crystal
forms, each of which shows different packing contacts, where the
position of DIII varies (83, 84). The binding sites for different lig-
ands and drugs are referred to either as fatty acid binding sites,
drug binding sites 1 and 2, or Sudlow’s sites 1 and 2, as highlighted
in Figure 2.
Under normal conditions, albumin carries 0.1–2.0 moles of
fatty acids, but it can bind more in case of disease (92, 93).
Structural analyses have shown that binding of fatty acids induces
conformational changes that may affect binding of other ligands
and drugs (94–99). As binding of FcRn engages two of the albu-
min domains, it raises an interesting question as to whether ligand
binding to albumin will affect receptor binding and transport
properties. Such knowledge is also of importance in design of
novel albumin-based therapeutics, so as to control their phar-
macokinetics. Interestingly, Schmidt and colleagues have shown
that saturation of albumin with fatty acids interferes greatly with
FcRn binding (72). This could be explained by steric hindrance,
as DIII contains a high-affinity fatty acid binding site, right where
the FcRn–W59 residue interacts (69, 72, 100). Thus, it is of great
importance to understand whether and how different endogenous
ligands and drugs are affecting the interaction with FcRn, as it
may well have significant impact on transport and deposition at
different body sites. The knowledge will certainly be important for
design of engineered albumin variants for various applications.
In addition,albumin has one free cysteine (C34) within a pocket
of DIA that is partly exposed (Figure 2). This free sulfhydryl group
is a site for binding of metals (Au and Pt) and nitric oxide (101,
102), but has also been conjugated to drugs (discussed later). The
C34 residue is not in proximity to the FcRn binding site on DI, but
it remains to be addressed whether conjugation to this site may
impact receptor binding and transport.
FcRn AS A HALF-LIFE REGULATOR
The direct involvement of FcRn as a homeostatic regulator of
IgG levels was first demonstrated in β2m-deficient mice (9, 10,
58). These mice do not express a functional FcRn and conse-
quently have reduced levels of circulating IgG as well as rapid
clearance of injected IgG (9, 10, 58). Later, inspection of mice
lacking the FcRn HC revealed a similar reduction in serum lev-
els of IgG and albumin (11, 103). These mice have serum levels
of IgG and albumin fourfold to fivefold and twofold to threefold
lower than that of normal mice, respectively (11, 103). Further
support for the great importance of FcRn for half-life regulation
was provided by a study of a rare human syndrome, named familial
hypercatabolic hypoproteinemia, diagnosed in two siblings from
a consanguineous marriage, who showed very low serum levels
of IgG and albumin that correlated with abnormally low expres-
sion of FcRn (104). The siblings carried a mutant β2m subunit
with an alanine to proline substitution at amino acid 11 in the
signal sequence, which resulted in 80–90% reduced expression of
β2m-associated proteins such as FcRn (12).
The plasma concentration of albumin in FcRn knock-out mice
is roughly half of that in normal mice (11, 105). In humans, the
average plasma concentration of albumin is 40 mg/ml (>600µM),
and as such a 70 kg person has a total albumin pool of 360 g,
where 120 g constitute the intravascular albumin, which is in con-
stant exchange with the extravascular pool. Studies in mice have
demonstrated that FcRn rescues an equivalent amount of albu-
min in a day as the liver produces, which is estimated for adult
humans to be 13 g per day (105). Thus, from an evolutionary per-
spective, the use of a common receptor to rescue IgG and albumin
from degradation is far more economical than using energy on
additional synthesis.
The serum levels of IgG and albumin are regulated by several
factors including their size above the renal clearance threshold
(discussed below), the balance between the rate of synthesis by
plasma cells and hepatocytes, and the level of FcRn expression.
Thus, if the serum level of albumin drops, the half-life should
increase due to increased rescue caused by less competition for
FcRn binding. This is indeed the case, and demonstrated in human
studies conducted in the 1950–1970, where the half-life of radiola-
beled albumin injected into people with abnormally low albumin
levels, was shown to be 50–100 days (106–108). In addition, using
so-called Nagase analbuminemic rats, which are genetically defi-
cient in albumin synthesis, the half-life of injected rat albumin was
measured to be 2.2 times longer than in normal rats (109, 110).
Moreover, the albumin gene exhibits a significant degree of
DNA mutations causing analbuminemia or alloalbuminemia.
More than 70 genetic variants have been characterized, and rep-
resent site-specific, splice-site, or frame-shift variants (111, 112).
Alloalbuminemia (bisalbuminemia) is an inherited or acquired
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condition characterized by the presence of altered albumin vari-
ants where heterozygotes have two forms of the protein. Further-
more, analbuminemia is a rare recessive disorder in which subjects
have little or no (<1 mg/ml) circulating albumin caused by a vari-
ety of mutations in the albumin gene, and is exhibited only by
homozygous subjects. Although albumin is the most common
serum protein, these conditions are benign, and surprisingly few
biochemical effects and clinical symptoms have been observed.
However, association between hypoalbuminemia and mortality
has been reported for patients with diseases such as acute heart
failure, renal disease, cancer, stroke, pneumonia, dementia, and
hemodialysis (113–117).
Several mutant albumin variants have been reported with
reduced half-life compared to wild-type albumin. One example
is the Casebrook variant, which has a single point mutation in the
C-terminal DIII (D494N), which introduces an N-glycosylation
site. In heterozygous carriers, only 35% of total serum albumin
corresponds to Casebrook (118, 119). We have recently shown
that this albumin variant has a twofold reduced affinity for FcRn,
which suggests that it will have shorter half-life in the presence
of normal albumin that will compete more efficiently for binding
to the receptor (70). This is supported by a study performed in
rabbits where the D494N mutation was introduced in rabbit albu-
min to the effect of reducing the half-life twofold compared with
normal albumin (4.7 versus 2.8 days) (119). Another example is a
truncated albumin variant, named Bartin, which lacks almost the
entire DIII, except for the first 25 amino acids, due to a nonsense
mutation (120). This variant, when recombinantly expressed, did
not show detectable binding to FcRn, which is in line with the
fact that DIII is the major binding domain for FcRn (89). In fact,
albumin variants with either C-terminal elongation or truncation
constitute only 2–30% of the total albumin in heterozygous car-
riers, which has been suggested to be caused by instability of the
abnormal albumin (89, 121, 122). However, it may well be due to
altered or lack of FcRn binding.
FcRn-MEDIATED RECYCLING AND TRANSCYTOSIS
The neonatal Fc receptor transports its ligands via either of two
distinct pathways, cellular recycling or transcytosis. Illustrations of
the FcRn-mediated recycling and transcytotic pathways are shown
in Figures 4A–C. The steps of the recycling process have been
studied using advanced live cell fluorescence imaging in human
endothelial cells over-expressing FcRn (123–128). These elegant
studies have revealed that FcRn predominantly resides within acid-
ified endosomes where it binds IgG that is taken up by fluid-phase
pinocytosis. The low pH within the endosomes triggers binding,
which results in recycling of the FcRn–IgG complex to the cell sur-
face where exposure to an increasingly more neutral environment
favors exocytosis of IgG out of the cell in a so-called kiss-and-run
or prolonged-release manner (125). By contrast, proteins that do
not bind FcRn will be sorted to late endosomes and subsequently
to lysosomes where they are degraded (124, 126). The process
is regulated by small Ras-like GTPases such as Rab4, Rab5, and
Rab11 that are present on FcRn containing endosomes, as indi-
cated in Figures 4A,B. Notably, Rab4 and Rab11 are known to be
involved in recycling from sorting endosomes to the plasma mem-
brane, whereas Rab5 is an early endosomal marker (129). Ward
and colleagues have shown that during exocytosis, FcRn is sorted
into tubulovesicular compartments that are positive for Rab4 and
Rab11, and that only Rab11 is associated with the receptor upon
exocytosis at the plasma membrane (127, 128). Importantly, the
studies have revealed that there is overlap between the Rabs in the
different compartments, so-called Rab conversion, as endosomes
mature (130).
As FcRn binds both IgG and albumin at independent bind-
ing sites, albumin is likely to follow the same pathway as IgG,
although so far, no imaging studies have been done on traffick-
ing of the ternary complex. The non-cooperative binding of the
ligands is illustrated using a high affinity 26-amino acid peptide
dimer SYN1436. The peptide binds to the IgG site of the receptor
and blocks FcRn-mediated transport of IgG, resulting in an 80%
reduction in serum levels of IgG in cynomolgus monkeys without
reducing serum albumin levels (131, 132).
Furthermore, this raises the question of which cells and organs
that contribute to FcRn-mediated salvage. So far, it has been shown
that both non-hematopoietic and hematopoietic cells are of equal
importance (49, 51). Studies in mice have identified endothelial
cells and myeloid-derived professional antigen presenting cells as
key players (49). When the expression of FcRn was conditionally
deleted from these cell types, the serum levels of IgG and albumin
were reduced by fourfold and twofold, respectively (49, 51). The
contribution of the different cell types will depend on the rate of
uptake, the level of FcRn expression, and the abundance of the
ligands. In addition, the expression of the receptor can be up- or
down-regulated by pro-inflammatory substances and cytokines,
which add another level of regulation (133, 134).
As initially described,FcRn binds IgG derived from the mother’s
milk and mediates transcytosis across the neonatal rat intes-
tine (135–137). While the expression of FcRn in the rodent
intestine is developmentally down-regulated, it is constitutive in
humans throughout life (21, 138, 139). Several studies have shown
that human FcRn can transport both monomeric IgG and IgG-
containing immune complexes across mucosal epithelial barriers
in both directions, a process that also relies on a pH gradient (19,
20, 23, 140, 141).
Using polarized Madin–Darby canine kidney cells that over-
express human FcRn, it has been demonstrated that the receptor
transports IgG from either apical or basolateral side into the recy-
cling endosome (75, 78). As shown in Figure 4B, the actin motor
myosinVb and the GTPase Rab25 regulate a sorting step that deter-
mines transcytosis without affecting recycling (142). In addition,
it was demonstrated that Rab11 is dispensable for transcytosis, but
regulates recycling to the basolateral side (142).
These findings raise the question of whether or not FcRn is
capable of mediating transcytosis of albumin across the same cel-
lular barriers, and whether the stoichiometry of the interaction
with FcRn plays a role, as albumin binds FcRn in a 1:1 manner,
while IgG is homodimeric and has two binding sites for FcRn
(11, 60). This is interesting, as albumin transport across epithelia
would allow for delivery of albumin-based therapeutics. How-
ever, no in vitro cellular studies have so far demonstrated that
FcRn can transport albumin efficiently alone or in the presence
of IgG across polarized cells. One study using MDCK cells over-
expressing rat FcRn could not detect transcytosis of rat albumin
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FIGURE 4 | FcRn-mediated transport pathways. (A) A schematic
illustration of the model of FcRn-mediated recycling pathway of its two
ligands in an endothelial cell lining the vascular space. (1) IgG and albumin
are taken up from the blood by pinocytosis in Rab5 positive early
endosomes. (2) FcRn, predominantly localized to acidified endosomes,
binds the ligands in Rab4 and Rab11 positive recycling compartments. (3)
The ternary complex is recycled to the cell surface as Rab11-positive
tubules, which results in exocytosis of the ligands. (4)The neutral pH of the
bloodstream leads to release of the ligands. (5) Proteins that do not bind to
the receptor will be sorted to late endosomes and further to lysosomes for
degradation. (B) An illustration of a polarized epithelial cell layer and the
model of FcRn-mediated bidirectional transport. (1) The acidic pH present
at certain mucosal sites (apical side) may result in binding of the ligands to
FcRn at the cell surface in addition to within recycling endosomes. (2) The
transcytotic pathway may be regulated by calmodulin that binds to the
cytoplasmic tail of FcRn, and (3) depends on the actin motor myosin Vb
and Rab25. (4) Endosomes fuse with the basolateral side of the cells,
which lead to release of the ligands upon exposure to neutral pH. (5) FcRn
may also transcytose IgG-containing immune complexes across the
polarized cell layer. (C)The illustration shows a DC that expresses both
FcRn and classical Fcγ receptors. (1) Cross-binding of an IgG-containing
immune complex to surface-expressed FcγRs leads to internalization into
early endosomes. (2) The immune complexes engage FcRn within
acidified endosomes. (3) FcRn directs the IgG-containing immune
complexes to loading compartments for processing followed by loading of
antigenic peptides onto MHC I (in terms of cross-presentation) and MHC
II. (4) MHC I and II traffic to the plasma membrane for presentation of
peptides to T-cells. (5) Monomeric ligands may also be recycled by DCs.
(78). Several studies have demonstrated that IgG-based fusions,
vaccines, and nanoparticles can be delivered in an FcRn-dependent
manner across mucosal barriers (25–32). Interestingly, in mice,
albumin was found in saliva (1–3.0µg/ml), feces (0.1 mg/ml),
and the small intestine (0.5 mg/ml) (143), and in a human study,
more albumin (655.0µg/ml) than IgG (50.0µg/ml) was found in
the fluid of the respiratory tract (144). Illustrations showing the
models for FcRn-mediated recycling and transcytosis are given in
Figures 4A–C.
THE ROLE OF FcRn IN THE KIDNEYS
Serum persistence of soluble proteins also depends on the renal
clearance threshold, which prevents clearance of proteins larger
than 60–70 kDa from the body through the urine. The nephron,
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its filtration barrier, and a model for protein reabsorption are illus-
trated in Figure 5. Specifically, the kidneys receive blood from the
renal arteries, which reach the glomerular filtration barriers that
form three size- and charge-selective filters. These block the pas-
sage of cells and larger proteins into the urine (145). First, the
blood is filtered in the glomerular capsule of the nephrons, and
then the filtrate is transported via the proximal convoluted tubule
where water and essential proteins are reabsorbed. As the kidneys
filter roughly 180 l of blood each day, it means that astonishing
>7 kg of albumin and >2 kg of IgG are processed by the kidneys.
The first study addressing a potential role of FcRn in the kid-
neys showed that the receptor is expressed in specialized epithelial
cells named podocytes (46), which are part of the glomerular
capsule, and the filtration barrier (Figure 5A). Akilesh and col-
leagues demonstrated that IgG accumulated at this barrier in mice
lacking FcRn (50). Based on this finding, FcRn-positive podocytes
were postulated to be the key cells responsible for removal of IgG
from the glomeruli. Notably, delayed clearance of IgG may lead
to serum-induced nephritis, which may indicate that the receptor
could be involved in the pathology of diseases such as systemic
lupus erythematosus, where kidney damage is commonly caused
by deposition of IgG and immune complexes at the glomerular
barrier. Thus, the presence of FcRn may provide a mechanism to
clear IgG from the glomerular basement membrane and deliver it
intact into the glomerular filtrate. Although the same study did not
address how albumin is handled, it has been shown that podocyte-
like epithelial cells endocytose albumin that co-localizes with FcRn
(146). The glomerular filtrate that enters the proximal convoluted
tubule is well known to contain albumin, and it has been demon-
strated that albumin is retrieved by proximal tubule cells (147).
FIGURE 5 |Transport of IgG and albumin in the kidneys. A schematic
cartoon showing the nephron of the kidney and transport pathways. Blood
enters the kidneys through the afferent arteriole from the renal artery,
proceeds through the capillaries of the glomerulus where filtration occurs,
and exits through the efferent arteriole. (A)The filtration barrier of the
glomerulus. (1) The first barrier is the fenestrations between endothelial
cells of the glomerular capillaries. (2) The second barrier is the basement
membrane, a non-cellular layer consisting of extracellular matrix
molecules, which make up charged pores. The podocytes are specialized
epithelial cells that encapsulate the capillaries and the basement
membrane, and form the outermost layer of epithelial cells facing the
glomerular filtrate. (3) The foot processes of the podocytes have slits
between them (slit diaphragms) that form the third layer of the filtration
barrier. (4) As the pore size of the barrier is between 60–70 kDa, close to
the size of albumin (66.5 kDa), some albumin passes the filter. (5)
Podocytes express FcRn, and may transcytose IgG and albumin to the
glomerular filtrate to prevent clogging of the filter. (B)The glomerular
filtrate enters the proximal tubuli where proximal tubular epithelial cells
lining the lumen of the tubuli are involved in reabsorption of albumin and
IgG, and thus prevent loss into the urine. (1) Proximal tubular epithelial cells
also express the cubilin/megalin receptor complex that binds albumin. (2)
In acidified endosomes, FcRn binds the ligands, and facilitate transcytosis.
(3)The ligands are delivered to the interstitial space of the kidneys followed
by drainage to lymphatic vessels and re-entry to the blood circulation.
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These cells also express FcRn (46), and several lines of evidence
support an important role of FcRn in retrieval of albumin (148–
150). The transport pathways of IgG and albumin in the nephron
are shown in Figure 5.
It has been demonstrated that FcRn-deficient mice secrete more
albumin into the urine than normal mice, and the same was
observed for normal mice transplanted with a kidney lacking FcRn
(150). When FcRn-deficient mice received an FcRn-expressing
kidney by transplantation, increased serum levels of albumin were
observed. In contrast, FcRn-deficient mice showed minimal uri-
nary excretion of IgG, which increased to normal levels when
knock-out mice were transplanted with a single FcRn express-
ing kidney (150). This may imply that the glomeruli get clogged
with IgG in the absence of FcRn, while it is otherwise transported
by the podocytes.
Furthermore, recent studies using a transgenic mouse strain
with podocyte-specific expression of doxycycline-inducible tagged
mouse albumin showed that albumin secreted into the filtrate is
subsequently reabsorbed by proximal tubular cells, which resulted
in increased serum levels (149). In addition, deletion of FcRn
expression abolished uptake of albumin, and also IgG in proxi-
mal tubular cells (148, 149). Collectively, these data support a key
role for FcRn in the kidney tubular system, where FcRn protects
albumin and IgG from being excreted into the urine, a mechanism
that likely relies on directed pH-dependent transcytosis of intact
ligands back to the circulatory system. Thus, the data point to the
first evidence of FcRn-mediated transcytosis of albumin as part of
a ternary complex with IgG.
However, the mechanisms responsible for handling albumin in
the kidneys may not necessarily rely on FcRn only, as several stud-
ies claim that uptake of albumin by the proximal tubular cells is
an active process that depends on a receptor complex consisting of
cubilin and megalin (151–154) (Figure 5B). Homozygous deletion
of cubilin in mice is lethal, and studies done in heterozygous indi-
viduals showed reduced renal proximal tubular uptake, increased
urinary loss, and decreased blood levels of albumin (152, 153).
Further, dogs with a defective cubilin gene excrete large amounts
of albumin due to an almost complete lack of reabsorption (153).
In addition, cubilin has been shown to associate with megalin,
and in line with this, both mice and humans deficient in megalin
expression have reduced tubular reabsorption of albumin (153,
155, 156). As illustrated in Figure 5B, these findings thus raise
the possibility that FcRn may work in concert with the megalin
and cubilin complex. Such a pathway may then serve as a selective
process where only albumin with intact receptor binding proper-
ties are returned to the blood, while albumin with bound ligands
is excreted in the urine or sorted to intracellular compartments
destined for degradation.
A REGULATORY ROLE OF FcRn IN THE LIVER?
The liver receives six times more blood per day than the kidneys
due to supply of both arterial blood from the heart, and venous
blood from the digestive tract. The main cell type (70–80%) of the
liver is specialized epithelial cells named hepatocytes, which have
an apical side facing the bile canaculi, and a basolateral side that
is in contact with the blood (157). This means that large amounts
of IgG and albumin are in direct contact with endocytically active
hepatocytes. As such, it is of great interest to address the impor-
tance of IgG and albumin receptors including FcRn in liver cells
in the context of IgG and albumin homeostasis.
Despite the fact that the amount of IgG in blood is five times
higher than that of IgA, astonishingly little IgG enters the bile com-
pared with secretory IgA (158). Likewise, even though albumin is
produced by hepatocytes that face both blood and bile ducts, the
level of albumin in blood is 100-fold higher than that found in the
bile (158, 159). However, there is a scarcity of data on which trans-
port mechanisms operate in hepatocytes to maintain serum to bile
ratio of IgG and albumin, rescuing these ligands from catabolism
and directing newly synthesized albumin to the blood. Only a few
papers have addressed the expression and function of FcRn in the
liver (53, 160, 161). One shows expression of FcRn in the rat liver
and that it binds IgG in a pH-dependent manner (53). Thus, there
is a great need for studies addressing the impact of FcRn in the
liver, so as to understand the biology and biodistribution of IgG
and albumin. In this context, it is highly interesting that the liver is
the principal site for albumin synthesis. Studies addressing these
aspects will shed new light on how to avoid liver toxicity.
THE ROLE OF FcRn IN IMMUNE CELLS
The neonatal Fc receptor is expressed in mouse and human
myeloid-derived antigen presenting cells such as monocytes,
macrophages, and dendritic cells (DCs) (42, 49, 51). Besides being
of importance in half-life regulation, FcRn in these cells has a
role in antigen presentation following uptake of IgG-containing
immune complexes (162, 163). The different sorting pathways
for IgG and IgG-containing immune complexes are illustrated in
Figure 4C. Whereas monomeric IgG is efficiently recycled by FcRn
in DCs, IgG-immune complexes are taken up following binding to
classical Fcγ receptors expressed on the cell surface, before FcRn
is recruited within acidified endosomes, followed by transport to
a degradative pathway leading to antigen loading on either MHC
class I or II for presentation to T cells (162, 163) (Figure 4C). In
particular, FcRn has been shown to be of great importance in cross-
presentation mediated by monocyte-derived CD8−CD11b+DCs,
a pathway that was recently shown to be critical in cancer protec-
tion in mice (164). The role of FcRn in antigen presentation has
been thoroughly reviewed elsewhere (163, 165).
Notably, the invariant chain (Ii) is an important regulator of
MHC class I and II transport (166, 167), and one study showed
FcRn association with Ii in DCs as well as in cytokine-stimulated
epithelial and endothelial cells (168). The association of the FcRn–
Ii complex was initiated within the ER, and Ii association targeted
the receptor to late endosomes or lysosomes. Thus, Ii may be a
modulator of FcRn trafficking of immune-complexes (168).
As efficient uptake and delivery of immune complexes to FcRn
is dependent on initial binding to the Fcγ receptor, it is of interest to
address whether albumin fusions or complexes are excluded from
this pathway or not. Interestingly, albumin has been shown to be
efficiently taken up by phagocytes of sentinel lymph nodes in mice,
and when conjugated as a vaccine it resulted in increased accumu-
lation in the lymph node followed by enhanced T-cell priming and
anti-tumor efficacy (169).
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THE ROLE OF FcRn AT IMMUNE-PRIVILEGED SITES
Immune-privileged sites are characterized by limited or absence
of immune surveillance and include the central nervous sys-
tem, the eyes, testis, and placenta. With regard to FcRn, confocal
microscopy studies have identified its expression in choroid plexus
epithelium, which forms part of the blood–brain-barrier (BBB)
(170), a finding, which suggested that the receptor may medi-
ate efflux of IgG from the brain to the blood in a process of
reverse transcytosis (171, 172). Indeed, in a murine model of
Alzheimer’s disease, it was shown that FcRn expressed within
the BBB is involved in the removal of amyloid β-peptide spe-
cific IgG-immune complexes from the brain of older mice (173).
However, another study is in conflict with this, and claims that
FcRn is not responsible for the low levels of IgG in the brain rel-
ative to that found in plasma (174, 175). A more recent study,
where IgG variants were injected intracranically in rats, showed
that an IgG with improved FcRn affinity was removed faster from
the brain compared to a mutant with no affinity for the receptor,
which was present for a longer time post injection (172). There-
fore, further studies are required to elucidate the function of FcRn
at the BBB.
The neonatal Fc receptor is also found to be expressed in the
eyes in a variety of tissues such as the cornea, lens epithelium, and
retinal blood vessel, but not in the retinal pigment epithelium and
the choroid (44, 52). Investigation in normal mice and mice defi-
cient for FcRn has demonstrated that the receptor plays a role in
removing intravitreally administered IgG via the blood retinal bar-
rier for delivery into the blood in analogy to the process of reverse
transcytosis described for the BBB (176). Another recent study
shows that retinal endothelial cells express FcRn, which may imply
that it is preventing IgG from transport across the blood–retinal
barrier (44).
As albumin is present in blood in higher levels than IgG, the
immune-privileged sites are exposed to both ligands; however,
none of the above studies addressed the importance of FcRn on
albumin transport at these barriers. In addition, the importance
of FcRn in the testis has yet not been addressed.
FcRn: A REGULATOR OF TRANSPLACENTAL TRANSPORT
The transfer of passive immunity from mother to offspring was
first attributed to the transfer of IgG across the intestine in neona-
tal rats via FcRn-mediated transcytosis, as discussed above. In
humans, IgG is delivered via the placenta, and a human ortholog of
FcRn was first cloned from specialized placental cells named syn-
cytiotrophoblasts, and later these cells were shown to bind IgG (22,
24, 177). However, to enter the fetal blood, IgG needs to cross not
only the syncytiotrophoblasts but also the fetal endothelium. In
addition to FcRn, another IgG binding receptor, Fcγ receptor IIB,
has been identified in placental endothelial cells and postulated
to be involved in the shuttle of IgG to the fetus, but conflicting
data exist (178–181). Using ex vivo placenta perfusions, it was
demonstrated that an IgG molecule with no affinity for classical
Fcγ receptors is transported across the placenta, while an IgG with
no affinity for FcRn is not (24). In addition, an engineered IgG
variant with improved affinity for FcRn was transported more
efficiently than wild-type IgG (182). These data strongly suggest
that transport of IgG is solely dependent on FcRn.
With regard to transfer of albumin, the literature is conflicting.
Early studies from the 1950–1960s conclude that transport of albu-
min to the fetus does not occur in mice, rats, and dogs (183–185),
while reports from studies in rabbits and rhesus monkeys show
that albumin is transported, although to a much lesser extent than
IgG (183, 186–188). More specifically, the levels of albumin in the
fetus of rabbits were found to be 40% of that of the levels of mater-
nally derived IgG (187), while in rhesus monkeys 15- to 20-fold
lower levels of albumin were detected compared with IgG (186). In
a human study from 1964, where radioiodinated IgG and albumin
were injected into pregnant women in the last month of gestation,
the levels of albumin in the offspring were measured to be only
14–15% of that found in the maternal blood, whereas the amounts
of IgG were slightly higher than that found in the mothers (189).
These studies indicate that there are differences across species, and
that albumin is inefficiently transported across the placenta com-
pared with IgG in rhesus monkeys and humans. Whether or not
other albumin binding receptors are involved in albumin trans-
port in the different cellular layers of the placenta is not known,
but two studies have identified the cubilin/megalin complex in
human syncytiotrophoblasts (190, 191). Hence, there is a great
need for in-depth studies addressing how albumin and albumin-
bound cargo are handled by the cells of the placenta. For instance,
the use of in vitro perfusion systems of human placenta combined
with current molecular methods may facilitate new insights into
the mechanisms at play.
THE IMPACT OF CROSS-SPECIES BINDING DIFFERENCES
As rodents are routinely used for pre-clinical screening of IgG
and albumin-based therapeutics prior to studies in primates, it
is necessary to understand how human IgG and human albumin
bind mouse and rat FcRn. Indeed, large differences in cross-species
binding exist that need to be considered prior to in vivo evaluation
of their pharmacokinetic and pharmacodynamic profiles (17, 18,
192). The importance of such cross-species differences was first
appreciated when it was found that human FcRn does not bind
to mouse IgG, while mouse FcRn binds human IgG more strongly
than mouse IgG, a finding that explains why human IgG has a
longer serum half-life in wild-type mice than mouse IgG (192–
194). On the other hand, the lack of binding of mouse IgG to
human FcRn gives an explanation for the disappointingly short
in vivo persistence of therapeutic mouse IgG in humans (195,
196). For in vivo evaluation of human IgG therapeutics, the state-
of-the-art mouse strains used are genetically modified as they lack
expression of mouse FcRn and instead are transgenic for human
FcRn (193, 197, 198). Injected human IgGs have a long half-life in
such mice, but their serum levels of endogenous IgG are low due
to lack of binding to mouse IgGs. A more complete and attractive
model would be mice that are transgenic for human IgG while also
express human FcRn.
Regarding albumin, recent studies have demonstrated that
FcRn from both mice and humans bind more strongly to mouse
albumin than to the human form, and that mouse FcRn binds
very poorly to human albumin (17, 18, 199). These findings are in
agreement with the fact that mice transgenic for human FcRn show
higher levels of mouse albumin in blood than normal mice (11),
and that the serum half-life of human albumin is similar to that
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of a human albumin variant (K500A) with considerably reduced
affinity toward human FcRn (18). Another example is that the
half-life of human albumin is only 15 h in normal rats compared
to 49 h for rat albumin (200). Consequently, rodents have limi-
tations as pre-clinical models for evaluation of human albumin
variants and albumin-based therapeutics, as injected variants will
be ignored by mouse FcRn in the presence of 40 mg/ml of endoge-
nous mouse albumin. Similarly, human FcRn transgenic mice will
rescue mouse albumin from degradation more efficiently than
injected human albumin. These are critical matters to consider
prior to evaluation of human albumin-based therapeutics. Thus,
there is a great need for construction of novel mouse strains that
are human FcRn transgenic and lack expression of mouse albu-
min, or where the gene for mouse albumin is replaced with the
human counterpart.
FcRn AND THERAPEUTIC APPLICATIONS
The versatile roles of FcRn are increasingly appreciated by both
academic labs and biotech companies, as new opportunities for
therapy become available. Many examples of utilization of the
biology of FcRn have given rise to new classes of IgG-based
therapeutics. In light of the expanding interest and mapping
of the relationship between FcRn and albumin, it is likely that
such knowledge will pave the way for tailoring of albumin-based
therapeutics.
As IgG is the fastest growing class of biotherapeutics, there is a
great interest for optimization of effector functions and in vivo effi-
cacy by manipulating the interaction with FcRn. As the interaction
is pH dependent, the major challenge has been to improve bind-
ing without disrupting pH-dependent binding. Despite this, sev-
eral examples exist on successful engineering by targeting amino
acid residues at the core or near the FcRn interaction site on
IgG (201–206).
The same principle has just been revealed for human albu-
min, by showing that swapping of part of DIII or introduction of
substitutions within DIII result in albumin variants with altered
FcRn-binding properties (18, 70, 72, 89, 199). The first exam-
ple of engineering was demonstrated by swapping DIII from
mouse albumin onto DI–DII of human albumin, which resulted
in a hybrid albumin with considerably improved binding toward
mouse and human FcRn, whereas swapping of DIII of human
albumin onto DI–DII of mouse albumin reduced binding consid-
erably (199). Moreover, swapping of a stretch of amino acids corre-
sponding to the last C-terminalα-helix of mouse albumin onto the
human counterpart gave rise to fourfold improved binding (199).
In another approach, yeast display was used to develop human
albumin variants with a range of affinities toward human FcRn.
One such variant (E505G/V547A) gained more than 10-fold
improved affinity at pH 6.0 with a minor increase at neutral pH,
which extended the half-life in human FcRn transgenic mice and
cynomolgus monkeys by 1.5-fold and 1.3-fold, respectively (72).
Notably, selected variants with three and four DIII substitutions
were immunogenic when injected into human FcRn transgenic
mice (72).
Furthermore, using an approach based on structural analysis
and cross-species binding analyses, a single substituted human
albumin variant (K573P) was identified with 12-fold improved
affinity toward human FcRn at acidic pH without detectable
binding at neutral pH (18). When evaluated in mice transgenic for
human FcRn and cynomolgus monkeys, the engineered variant
showed 1.4 and 1.6-fold extended half-life, respectively. Inter-
estingly, replacement of K573 with any amino acid resulted in
enhanced binding to human FcRn at acidic pH, a finding that is not
easily explained based on the available co-crystal structures (18, 69,
72). Also, from an evolutionary perspective, it is interesting that
all species have a proline at position 573, except for humans and
orangutans. Notably, introduction of K573P in human albumin
improved binding to mouse FcRn by more than 20-fold, demon-
strating the importance of a proline at this position for optimal
binding to mouse FcRn, and it explains partly why human albumin
binds the mouse receptor poorly (17, 18). Interestingly, mutating
amino acid residues in a loop of DI to alanines resulted in HSA
variants with slightly improved binding to the receptor, and com-
bining mutations in DI and DIII may thus give rise to variants
with further improved FcRn binding properties (90).
ALBUMIN TARGETING AND THERAPEUTICS
The therapeutic efficacy of small proteins, peptides, and chem-
ical drugs is hampered by short in vivo serum half-life as they
are cleared rapidly by the kidneys or the liver. Two strategies for
rescue are fusion to Fc or albumin. Such approaches have been
extensively explored, and Fc-fused drugs are approved for clinical
use. An example is Fc-fusion to the tumor necrosis factor (TNF)
receptor (Etanercept, Enbrel®), which blocks binding of TNF-α to
cellular TNF receptor and thus inhibits pro-inflammatory activ-
ity in rheumatoid arthritis patients (207). Fc-fused therapeutics
and vaccines have also been shown to cross mucosal barriers in
an FcRn-dependent manner (25–32). Although such fusions bind
FcRn, the biophysical nature of the fused drug may alter binding
to FcRn (208).
In regard to albumin, its properties have been utilized in five
distinguished drug delivery technologies; (1) genetic fusion to the
N- or C-terminal end, (2) chemical coupling of low-molecular
weight drugs, (3) association of drugs with hydrophobic pockets
of albumin, (4) association of albumin-binding domains (ABDs)
that are genetically fused to drugs, and (5) encapsulation of drugs
into albumin nanoparticles (15, 16).
A number of reports exist on genetic fusion of therapeutic
proteins to wild-type albumin. Examples are hirudin (209), CD4
(210), insulin (211), growth hormone (212), granulocyte colony
stimulating factor (213), α and β interferons (214–216), and
antibody fragments (217–221). All have shown improved phar-
macokinetics compared to non-fused counterparts. For instance,
recombinant interferon α2a has only a half-life of 4 h in humans,
which is increased to 141 h when fused to albumin (214). Another
example is recombinant coagulation factors that have very short
half-life in humans. For instance, commercially available recom-
binant FVIIa (NovoSeven®) has a half-life of only 2.4 h (222).
As a result, patients require multiple and frequent infusions to
manage bleeding episodes. But when the factors are fused to the
N-terminal end of albumin via flexible glycine serine linkers, they
maintain activity and gain considerably extended half-life in both
pre-clinical animals and humans (222–224). Such fusions have
now entered clinical trials for treatment of hemophilia (225). In
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addition, the first albumin fusion that has entered the market is a
fusion of glucagon-like peptide-1 (GLP-1) to wild-type albumin
(Eperzan®/Tanzeum®), which was approved for treatment of type
II diabetes in 2014 (226, 227). These examples pinpoint that the
albumin fusion platform is a successful strategy for improving the
in vivo efficacy of small therapeutic proteins. In addition, a favor-
able feature of genetic fusion is that it allows a simple one-step syn-
thesis process with no need for in vitro chemical cross linking steps.
Such fusions were designed and constructed long before the
relationship between albumin and FcRn was appreciated. This
raises the question of whether genetic fusion of proteins to the N or
C-terminal end of albumin, or both, compromises pH-dependent
binding to FcRn. One study has so far addressed this concern,
where direct fusion of a peptide or an antibody single-chain vari-
able fragment (scFv) via a linker to the N-terminal end gave no or
only a minor reduction in binding affinity at acidic pH, whereas
fusion to the C-terminal had a more pronounced effect and at
most twofold weaker affinity (199). Although the decrease in bind-
ing was minor, it may play a role in vivo when fusions are injected
into animals or humans where it will compete for binding to FcRn
in the presence of 40 mg/ml of endogenous albumin. Thus, bind-
ing to FcRn should be addressed for each fusion as the nature of
various fusion partners may affect receptor binding differently.
The presence of high amounts of albumin at the site of tumors
and inflamed tissues has been utilized for tumor targeting by
chemical conjugation of drugs to albumin (228). One example
is methotrexate for treatment of renal carcinomas and autoim-
mune diseases such as rheumatoid arthritis (229–231). It is likely
that random conjugation of payloads to surface exposed amino
acid residues on albumin will negatively affect clearance and FcRn
transport. Another approach is nab-paclitaxel (Abraxane®), which
is composed of the lipophilic drug paclitaxel that is encapsulated
with albumin under high pressure. The drug was approved in 2005
for treatment of metastatic breast cancer, and is currently in tri-
als for treatment of non-small lung cancer, pancreas cancer, and
melanoma (16, 232–236). Following administration, the nanopar-
ticles dissociate and paclitaxel becomes associated with albumin
in blood. Whether nanoparticles containing albumin are capable
of interacting with FcRn remains to be addressed.
A more specific way to chemically target albumin is to utilize
the free C34 on the DI of albumin. For instance, in the technology
known as Drug Affinity Complex (DAC®), drugs are specifically
and stably conjugated to either exogenous or endogenous albumin
(237). One such DAC-based drug is exendin-4, which is a GLP-1
homolog (CJC–1131) for treatment of type 2 diabetes that has
entered clinical trials (238–240). The power of this technology is
mirrored by the pharmacokinetics in humans, where the half-lives
of GLP-1 analogs have been shown to be a few hours compared
with 9–15 days for the C34-bound drug (241). Another example
is an acidic sensitive prodrug of doxorubicin (Aldoxorubicin) that
is rapidly bound to C34 after intravenous administration (237).
The drug is conjugated via a linker that is cleaved upon exposure
to an acidic environment as found in tumor tissues, and Aldox-
orubicin is currently in clinical trials for treatment of sarcoma
and glioblastoma (16). Whether the acidic-sensitive linker is pro-
tected or cleaved during FcRn-mediating transport remains to be
investigated.
A more recent example is a designed ankyrin repeat protein
(DARPin) with specificity for the epithelial cell adhesion molecule
that has been modified in the N-terminal end by introduction
of the non-natural amino acid azidohomoalanine. The modifica-
tion enables linkage of site-specifically dibenzocyclooctyne to C34
of wild-type mouse albumin (242). The conjugate was shown to
bind mouse FcRn, a strategy that extended the serum half-life of
the DARPin from 11 min to 17.4 h in mice (242). As discussed
above, targeting of C34 will presumably not interfere with FcRn
binding and transport.
Albumin may also be utilized by reversible non-covalent asso-
ciation. Such a strategy excludes the need for in vitro conjugation
as endogenous albumin is targeted post injection (243–245). One
strategy is to utilize fatty acids as tags that can be conjugated to
drugs, and association with albumin post injection, which results
in extended half-life. An example is conjugation of a myristate
tag to a lysine residue on the insulin analog detemir (Levemir®),
which is approved for treatment of diabetes types 1 and 2 (243, 246,
247). At the time of subcutaneous administration, the drug exists
as hexamers that dissociate into monomers in blood and associate
with circulating albumin. The procedure prolongs the half-life
from 5–6 min for the peptide to 5–7 h for the albumin-targeted
drug (15). Similar strategies using fatty acids as tags with improve-
ment in pharmacokinetics have been described for insulin-based
drugs (Tresiba® and Victoza®) (248, 249).
Furthermore, an albumin-binding minimal organic molecule
[2-(3-maleimidopropanamido)-6-(4-(4-iodophenyl)butanamido)
hexanoate] that has been chemically conjugated to a free cysteine
residue engineered into the C-terminal end of an scFv fragment
with tumor specificity, was shown to increase the half-life from
0.5 to 16.6 h in mice (250). In addition, the modified scFv showed
superior tumor accumulation in tumor-bearing mice (250).
An alternative is to target albumin with anti-albumin binding
antibody fragments (221). An illustrating example is a bi-specific
F(ab)2 fragment with one-arm that targets TNF and one that tar-
gets albumin, which showed a half-life fivefold longer than that
of mono-specific anti-TNF F(ab)2. This half-life is comparable to
that of rat albumin itself (42.5 versus 49.1 h, respectively), which
supports that the anti-albumin Fab does not interfere with FcRn
binding and transport (221).
The same has been demonstrated using small albumin-binding
domain (ABD) antibodies (11–13 kDa; AlbudAb®) selected to
bind rat albumin with high affinity (13 nM). The half-life in rats
is 53 h, which is equal to the half-life measured for albumin (53 h)
(200). Notably, it has been demonstrated that this AlbudAb binds
to the DII of albumin, which is not engaged in FcRn binding (200,
251). So-called nanobodies with specificity for albumin have also
been selected (252).
Moreover, small peptides with specificity for albumin from
several species have been selected using phage display technol-
ogy, where the core sequence (DICLPRWGCLW) is functionally
dependent on a disulfide bridge between the two cysteine residues
(253). One of the selected peptides (SA21) had a half-life of 2.3 h
in rabbits, significantly longer than the 7.3 min of an unrelated
peptide of similar size (253). Moreover, when albumin binding
peptides with a wide range of affinities were fused to a Fab, with
specificity for human epidermal growth factor receptor 2 (HER2)
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(AB.Fab4D5) derived from the clinically approved trastuzumab
(Herceptin®), a correlation between albumin affinity and serum
half-life was demonstrated, as fusions with peptides of low affinity
were eliminated faster than fusions with strongly binding peptides
(254). These data show that the pharmacokinetics of a protein of
interest may be tailored as a function of albumin affinity.
Furthermore, AB.Fab4D5 has been tested for its ability to target
HER2-positive tumors in allograft mouse models, and demon-
strated rapid tumor targeting in addition to elimination from the
blood faster than the parental antibody (255). Thus, a significantly
improved tumor to normal tissue ratio was achieved. Notably,
Fab4D5 accumulated in the kidneys, while AB.Fab4D5 did not,
suggesting that the albumin binding peptide has a great impact
on biodistribution and organ deposition (255). These effects may
be explained by the increase in size above the threshold for renal
clearance and maintained albumin binding to FcRn.
Another approach has been to utilize the ABD derived from
Streptococcus protein G. For instance, anti-HER2 Fab4D5 has been
genetically fused via its light chain C-terminal end to such an ABD,
which prolonged the half-life to 21 h compared to only 2 h for the
naked Fab4D5 in mice, and comparable to that obtained with
Fab4D5 fused to albumin targeting peptides (255, 256). Also, less
ABD-fused Fab4D5 accumulated in the kidneys relative to naked
Fab4D5.
A similar approach has been used to improve the pharmaco-
kinetics of a divalent anti-HER2 Affibody (ZHER2:342) molecule
genetically fused to ABD. An Affibody is a small scaffold (~7 kDa)
derived from the IgG binding domain of staphylococcal protein A
that is used for construction of combinatorial libraries and target
selections (257). Interestingly, high tumor uptake of radiolabeled
anti-HER2 Affibody (ZHER2:342) fused to ABD was demonstrated
in HER2-positive microxenograft mice, where 25-fold reduction
in kidney accumulation compared with the Affibody lacking ABD
was observed (258). Thus again, non-covalent association with
albumin was used to redistribute the therapeutic agent to avoid
kidney accumulation. In regard to FcRn, it has been demon-
strated that ABD, both alone and when fused to anti-HER2 Affi-
body (ZHER2:342), binds albumin independently of pH-dependent
binding to FcRn (259). Furthermore, FcRn binding was unaf-
fected by the presence of IgG, and the ABD fusion showed a
similar biodistribution profile as rat albumin in wild-type rats
(259). Thus, these data strongly indicate that the anti-albumin
peptides and ABD bind FcRn properly when fused to a protein
of interest. However, this should be addressed in each case as
to rule out that the fusion partner causes steric hindrance or
otherwise negatively affect FcRn binding. Importantly, to allow
efficient FcRn-mediated recycling and transcytosis, the albumin
binding molecules need to bind albumin not only at physiologi-
cal pH but also at the mildly acidic pH found within endosomal
compartments. The latter was addressed for the albumin bind-
ing peptides, where no differences in affinity were detected as a
function of pH (253).
CONCLUDING REMARKS
The neonatal Fc receptor is a unique cellular receptor with
affinity for IgG and albumin, two completely unrelated plasma
proteins. Both ligands bind the receptor in a remarkably
similar pH-dependent manner, which is fundamental for the
versatile functions spanning both immunological and non-
immunological processes. It is broadly expressed and functions in
both hematopoietic and non-hematopoietic cells, including spe-
cialized cell types of vital organs such as the kidneys, liver, and
placenta, which highlight the importance of the receptor in home-
ostatic regulation of the ligands throughout the body. However,
further studies are needed to obtain a more complete understand-
ing of the roles of FcRn at every body site, and also the potential
impact of other albumin receptors.
Furthermore, our molecular understanding of how FcRn binds
its ligands and controls their half-life has prompted engineer-
ing of new classes of IgG molecules with unique blocking and
transport properties. The recent elucidation of the FcRn–albumin
relationship also offers opportunities for refining existing albu-
min technologies or development of completely new concepts.
Recently, engineered albumin variants with altered FcRn binding
kinetics were shown to result in extended serum half-life beyond
that of natural albumin. This has triggered enthusiasm as these
may be used as fusion partners to gain superior pharmacokinetics
of both biotherapeutics and chemical drugs. These findings will
surely encourage further molecular engineering of albumin vari-
ants with tailored pharmacokinetic properties. Recent knowledge
about the FcRn–albumin interaction and its key role in home-
ostatic regulation will also allow reinterpretation of previously
published data on conjugation of payloads, as disruption of the
interaction with FcRn will undoubtedly have a major impact on
their in vivo behavior. Especially, pre-clinical in vivo studies of
human albumin-based therapeutics in mice or rats need to be
reassessed since rodent FcRn binds only weakly to human albu-
min, which will compete poorly for binding to the mouse receptor
in the presence of larger amounts of endogenous mouse albumin.
Thus, for future studies, there is a great need for new transgenic
pre-clinical animal models suitable for studies of human albumin
variants and human albumin-based therapeutics.
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